Skip to main content
PMC home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1998;6(6):237–243. doi: 10.1002/(SICI)1098-0997(1998)6:6<237::AID-IDOG3>3.0.CO;2-E

Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy.

N S Silverman 1, D H Watts 1, J Hitti 1, D M Money 1, E Livingston 1, J Axelrod 1, J M Ernest 1, D Robbins 1, M M DiVito 1
PMCID: PMC1784818  PMID: 9972484

Abstract

OBJECTIVE: To study maternal and neonatal effects of combination nucleoside analog therapy administered to human immunodeficiency virus (HIV)-infected pregnant women for maternal indications. METHODS: A multicenter, prospective observational study was undertaken at six perinatal centers in the United States and Canada that supported regional referral programs for the treatment of HIV-infected pregnant women. Demographic, laboratory, and pregnancy outcome data were collected for 39 women whose antiretroviral treatment regimens were expanded to include more than one nucleoside analog for maternal indications. The 40 newborns were monitored at pediatric referral centers through at least three months of age to ascertain their HIV infection status. RESULTS: For all 39 women, zidovudine (ZDV) therapy was instituted at 13.4 +/- 8.2 weeks, with a second agent (lamivudine [3TC] in 85% of cases) being added at a mean gestational age of 17.6 weeks. Duration of therapy with two agents was 20.6 +/- 10.4 weeks overall, with no women stopping medications because of side effects or toxicity. No significant changes in maternal laboratory values were seen, except for an increase in mean corpuscular volume, over the course of pregnancy. No clinically significant adverse neonatal outcomes were noted, with all but the three preterm newborns leaving hospital with their mothers. Neonatal anemia (hematocrit < 50%) was seen in 62% of newborns, with no children needing transfusion; mild elevations of liver function tests, primarily aspartate aminotransferase, were noted in 58% of newborns tested, though none were clinically jaundiced. Overall rate of neonatal HIV infection was 2.5% (95% confidence interval: 0.1-13.2%). CONCLUSION: Combination antiretroviral therapy during pregnancy with two nucleoside analogs was well-tolerated by mothers and newborns, with no significant short-term toxicities or side effects noted. Surveillance of exposed newborns' hematologic and liver function appears warranted.

Full Text

The Full Text of this article is available as a PDF (599.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloom S. L., Dias K. M., Bawdon R. E., Gilstrap L. C., 3rd The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol. 1997 Feb;176(2):291–293. doi: 10.1016/s0002-9378(97)70487-3. [DOI] [PubMed] [Google Scholar]
  2. Boyer P. J., Dillon M., Navaie M., Deveikis A., Keller M., O'Rourke S., Bryson Y. J. Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA. 1994 Jun 22;271(24):1925–1930. [PubMed] [Google Scholar]
  3. Cao Y., Krogstad P., Korber B. T., Koup R. A., Muldoon M., Macken C., Song J. L., Jin Z., Zhao J. Q., Clapp S. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997 May;3(5):549–552. doi: 10.1038/nm0597-549. [DOI] [PubMed] [Google Scholar]
  4. Carpenter C. C., Fischl M. A., Hammer S. M., Hirsch M. S., Jacobsen D. M., Katzenstein D. A., Montaner J. S., Richman D. D., Saag M. S., Schooley R. T. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997 Jun 25;277(24):1962–1969. [PubMed] [Google Scholar]
  5. Coll O., Hernandez M., Boucher C. A., Fortuny C., de Tejada B. M., Canet Y., Caragol I., Tijnagel J., Bertran J. M., Espanol T. Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jan 1;14(1):26–30. doi: 10.1097/00042560-199701010-00005. [DOI] [PubMed] [Google Scholar]
  6. Connor E. M., Sperling R. S., Gelber R., Kiselev P., Scott G., O'Sullivan M. J., VanDyke R., Bey M., Shearer W., Jacobson R. L. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173–1180. doi: 10.1056/NEJM199411033311801. [DOI] [PubMed] [Google Scholar]
  7. Eron J. J., Jr The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS. 1996 Dec;10 (Suppl 5):S11–S19. doi: 10.1097/00002030-199612005-00003. [DOI] [PubMed] [Google Scholar]
  8. Fiscus S. A., Adimora A. A., Schoenbach V. J., Lim W., McKinney R., Rupar D., Kenny J., Woods C., Wilfert C. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA. 1996 May 15;275(19):1483–1488. [PubMed] [Google Scholar]
  9. Kumar R. M., Hughes P. F., Khurranna A. Zidovudine use in pregnancy: a report on 104 cases and the occurrence of birth defects. J Acquir Immune Defic Syndr. 1994 Oct;7(10):1034–1039. [PubMed] [Google Scholar]
  10. Matheson P. B., Abrams E. J., Thomas P. A., Hernán M. A., Thea D. M., Lambert G., Krasinski K., Bamji M., Rogers M. F., Heagarty M. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis. 1995 Aug;172(2):353–358. doi: 10.1093/infdis/172.2.353. [DOI] [PubMed] [Google Scholar]
  11. Mayaux M. J., Dussaix E., Isopet J., Rekacewicz C., Mandelbrot L., Ciraru-Vigneron N., Allemon M. C., Chambrin V., Katlama C., Delfraissy J. F. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. J Infect Dis. 1997 Jan;175(1):172–175. doi: 10.1093/infdis/175.1.172. [DOI] [PubMed] [Google Scholar]
  12. Mellors J. W., Muñoz A., Giorgi J. V., Margolick J. B., Tassoni C. J., Gupta P., Kingsley L. A., Todd J. A., Saah A. J., Detels R. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997 Jun 15;126(12):946–954. doi: 10.7326/0003-4819-126-12-199706150-00003. [DOI] [PubMed] [Google Scholar]
  13. Minkoff H., Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol. 1997 Feb;176(2):478–489. doi: 10.1016/s0002-9378(97)70519-2. [DOI] [PubMed] [Google Scholar]
  14. Perry C. M., Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 1997 Apr;53(4):657–680. doi: 10.2165/00003495-199753040-00008. [DOI] [PubMed] [Google Scholar]
  15. Simpson B. J., Shapiro E. D., Andiman W. A. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):145–152. doi: 10.1097/00042560-199702010-00007. [DOI] [PubMed] [Google Scholar]
  16. Sperling R. S., Shapiro D. E., Coombs R. W., Todd J. A., Herman S. A., McSherry G. D., O'Sullivan M. J., Van Dyke R. B., Jimenez E., Rouzioux C. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996 Nov 28;335(22):1621–1629. doi: 10.1056/NEJM199611283352201. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES